American Century Companies
TRVI icon

American Century Companies’s Trevi Therapeutics TRVI Stock Holding History

American Century Companies’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-79,796
Closed -$502K – 2942
2025
Q1 		$502K Buy
79,796
+1,653
+2% +$7.88K ﹤0.01% 2508
2024
Q4 		$322K Buy
78,143
+24,153
+45% +$77.3K ﹤0.01% 2662
2024
Q3 		$180K Sell
53,990
-118
-0.2% -$351 ﹤0.01% 2776
2024
Q2 		$161K Buy
54,108
+7,902
+17% +$22K ﹤0.01% 2769
2024
Q1 		$159K Buy
46,206
+25,143
+119% +$56.1K ﹤0.01% 2801
2023
Q4 		$28.2K Sell
21,063
-364
-2% -$551 ﹤0.01% 2866
2023
Q3 		$46.7K Buy
+21,427
New +$48.4K ﹤0.01% 2811

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

American Century Companies's TRVI Position: Q2 2025 in Review

American Century Companies sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 79,796 shares — an estimated $502K sold.

American Century Companies first reported a position in TRVI in Q3 2023 and held it in 7 quarters. The position peaked at $502K in Q1 2025. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • American Century Companies reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • American Century Companies sold 79,796 Trevi Therapeutics shares in Q2 2025, an estimated $502K.
  • American Century Companies first reported a position in Trevi Therapeutics in Q3 2023 and held it in 7 quarters.
  • American Century Companies's Trevi Therapeutics position peaked at $502K in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on American Century Companies's 13F filing for Q2 2025, filed 12 Aug 2025.